Neurology Articles

Neurology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Brandes JL et al. - Women with a documented inadequate response to triptans for acute MM treatment were included in this placebo-controlled, parallel-group trial. Women were randomized to double-blind treatment for three perimenstrual periods (PMPs) with either frovatriptan 2.5 mg (q.d. or b.i.d.) or placebo initiated 2 days before anticipated MM. Both frovatriptan regimens were well tolerated. In women with difficult-to-treat MM, a 6-day regimen of frovatriptan significantly reduced MM incidence and severity.

Related Articles

Menstrual migraine pattern may start in adolescence
Internet Source, 11/12/09    Relevance Score: 70%

Menstrual migraine pattern may start in adolescence
Internet Source, 11/10/09    Relevance Score: 68%

Safety and Tolerability of Short-Term Preventive Frovatriptan: A Combined Analysis
Headache: The Journal of Head and Face Pain, 10/15/09    Relevance Score: 68%

Increased Dopamine Is Associated With the cGMP and Homocysteine Pathway in Female Migraineurs
Headache: The Journal of Head and Face Pain, 10/07/09    Relevance Score: 64%

Topiramate in migraine progression
The Journal of Headache and Pain, 10/21/09    Relevance Score: 48%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address